Bicara Therapeutics Common Stock Price To Earnings To Growth
| BCAX Stock | 20.01 0.78 3.75% |
Bicara Therapeutics Common fundamentals help investors to digest information that contributes to Bicara Therapeutics' financial success or failures. It also enables traders to predict the movement of Bicara Stock. The fundamental analysis module provides a way to measure Bicara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bicara Therapeutics stock.
Bicara |
Bicara Therapeutics Common Company Price To Earnings To Growth Analysis
Bicara Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Bicara Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Bicara Therapeutics is extremely important. It helps to project a fair market value of Bicara Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Bicara Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bicara Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bicara Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, Bicara Therapeutics Common has a Price To Earnings To Growth of 0.0 times. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Bicara Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bicara Therapeutics' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bicara Therapeutics could also be used in its relative valuation, which is a method of valuing Bicara Therapeutics by comparing valuation metrics of similar companies.Bicara Therapeutics is currently under evaluation in price to earnings to growth category among its peers.
Bicara Fundamentals
| Current Valuation | 577.25 M | ||||
| Shares Outstanding | 54.39 M | ||||
| Shares Owned By Insiders | 0.42 % | ||||
| Number Of Shares Shorted | 2.07 M | ||||
| Price To Book | 2.15 X | ||||
| EBITDA | (58.3 M) | ||||
| Total Debt | 382.75 M | ||||
| Book Value Per Share | (5.10) X | ||||
| Earnings Per Share | (3.75) X | ||||
| Market Capitalization | 1.1 B | ||||
| Total Asset | 233.98 M | ||||
| Retained Earnings | (153.02 M) | ||||
| Working Capital | 215.99 M | ||||
| Net Asset | 233.98 M |
About Bicara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bicara Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bicara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bicara Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.